8-K: Forian Reports Strong Q3 2025 Results, Reaffirms Outlook

Forian Inc. announced robust third-quarter 2025 financial results, showcasing significant revenue growth and improved Adjusted EBITDA, while reconfirming its full-year 2025 outlook.

Summary

• Revenue for the third quarter of 2025 was $7.8 million, a 66% increase from $4.7 million in the prior year's third quarter.
• Net loss for Q3 2025 was $(0.2) million, or $(0.00) per share, an improvement compared to a net loss of $(0.2) million, or $(0.01) per share, in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $0.5 million, representing a 153% increase from $0.2 million in the prior year's third quarter.
• Cash, cash equivalents, and marketable securities totaled $28.2 million as of September 30, 2025.
• Forian reconfirmed its full-year 2025 outlook, expecting revenue to be at the higher end of the previously reported range of $28 million to $30 million.
• Adjusted EBITDA for the full year 2025 is expected to be at the higher end of the previously reported range of $(1.0) million to $1.0 million.

Sentiment

Score: 8

Explanation: The company reported strong Q3 2025 financial results with significant revenue growth and a substantial increase in Adjusted EBITDA. The reconfirmation of the full-year outlook at the higher end of previous ranges indicates positive momentum and management confidence, despite still reporting a net loss.

Positives

• Achieved significant revenue growth of 66% year-over-year in Q3 2025, reaching $7.8 million.
• Improved net loss per share from $(0.01) in Q3 2024 to $(0.00) in Q3 2025.
• Adjusted EBITDA increased substantially by 153% year-over-year in Q3 2025, reaching $0.5 million.
• Maintained a strong cash position with $28.2 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Reconfirmed full-year 2025 outlook for both revenue and Adjusted EBITDA at the higher end of previously reported ranges, indicating management confidence.
• Achieved meaningful growth in Health Economics and Outcomes Research (HEOR) through new information integrations, client renewals, and expanded project scopes.
• Advanced partnerships with large health and pharma services companies to broaden real-world data coverage and enhance evidence-generation capabilities.
• Successfully introduced new data-driven financial analytics offerings and secured key contracts, positioning for continued diversification and market penetration in financial services.

Negatives

• Continued to report a net loss of $(0.2) million for Q3 2025 and $(1.05) million for the nine months ended September 30, 2025.
• Total assets decreased from $47.17 million at December 31, 2024, to $41.25 million at September 30, 2025.
• Marketable securities decreased from $30.49 million at December 31, 2024, to $23.56 million at September 30, 2025.
• Accounts payable significantly increased from $0.98 million at December 31, 2024, to $2.11 million at September 30, 2025.

Risks

• Risks and uncertainties associated with operations, strategy, and goals.
• Ability to execute on strategy.
• The outcome of the Company's completion of the quantification and evaluation of the specific impact of the restatement, including the possibility of material adjustments thereto.
• The discovery of additional and unanticipated information during the procedures required to be completed before the Company is able to file its 2024 Form 10-K.
• General risks and uncertainties set forth in Forian's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on April 11, 2025, and elsewhere in Forian’s filings and reports with the SEC.

Future Outlook

Forian reconfirmed its full-year 2025 outlook, expecting revenue to be at the higher end of the $28 million to $30 million range and Adjusted EBITDA to be at the higher end of the $(1.0) million to $1.0 million range.

Management Comments

• "Our third quarter performance demonstrates consistent progress and execution."
• "We continue to advance our business, deepen our core relationships in core markets, and build momentum across our business lines."
• "Our focus remains on driving both organic growth and strategic investments that enhance our platform and unlocking greater value throughout the healthcare landscape."

Industry Context

Forian operates in the data science and analytics space, serving life science, healthcare, and financial services industries. The reported growth in Health Economics and Outcomes Research (HEOR) and Health Services & Delivery aligns with broader industry trends emphasizing real-world data, evidence generation, and data-driven decision-making in healthcare. The expansion into financial services analytics demonstrates a strategic diversification, leveraging core data expertise across different high-value sectors, indicating adaptability and a broad market approach.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global industry benchmarks.

Legal Proceedings

• Litigation settlements and related expenses are mentioned in the income statement and are excluded from Adjusted EBITDA, primarily related to entities acquired in the Helix merger.

Related Party Transactions

• Convertible notes, with $6,000,000 in principal previously held by a related party, were redeemed as of September 30, 2025.

Stakeholder Impact

• Shareholders: Positive financial results and outlook could lead to increased investor confidence and potential share price appreciation.
• Customers: Expanded HEOR and Health Services & Delivery partnerships, along with new financial analytics offerings, suggest enhanced product/service offerings and deeper client relationships.
• Employees: Continued business advancement and growth could imply job stability and potential opportunities.
• Creditors: Redemption of convertible notes reduces debt, improving the company's financial health.

Next Steps

• Host a conference call and webcast at 4:30 p.m. ET on November 14, 2025, to discuss financial results with the investment community.
• Continue to advance business, deepen core relationships in core markets, and build momentum across business lines.
• Focus on driving both organic growth and strategic investments that enhance the platform and unlock greater value throughout the healthcare landscape.

Key Dates

Recommendation

Forian Inc. demonstrated robust performance in Q3 2025 with substantial revenue growth of 66% and a 153% increase in Adjusted EBITDA. The reconfirmation of the full-year outlook at the higher end of previous ranges signals strong management confidence and operational momentum. Strategic advancements in HEOR, Health Services & Delivery, and Financial Services indicate a diversified growth strategy. While the company still reports a net loss, the significant improvement in profitability metrics and strong cash position make it an attractive investment for growth-oriented investors.

Keywords

Forian Inc., FORA, Financial Results, Q3 2025, Earnings, Data Science, Healthcare Analytics, Life Science, Financial Services, Adjusted EBITDA, Revenue Growth, SEC Filing